seen from United States
seen from China
seen from India
seen from Sri Lanka
seen from South Korea
seen from Malaysia
seen from United States
seen from United States
seen from T1
seen from Türkiye
seen from Malaysia
seen from Vietnam
seen from United Kingdom
seen from Greece
seen from Sri Lanka
seen from China
seen from Philippines
seen from China
seen from United Kingdom
seen from China
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains
This article was written by Follow My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in…
Galectin: With Time Ticking, A Accomplice Is Wanted To Revitalize MASH Program
This text was written by Comply with Edmund Ingham is a biotech marketing consultant. He has been masking biotech, healthcare, and pharma for over 5 years, and has put collectively detailed reviews of over 1,000 corporations. He leads the investing group Haggerston BioHealth. The group is for each novice and skilled biotech traders. It offers catalysts to look out for and purchase and promote…
Galectin slumps after NASH drug misses main goal of mid... - https://goo.gl/xiHT71 - #Drug, #Galectin, #Goal, #Main, #Mid, #Misses, #NASH, #Nutrition, #Slumps
Galectin says NASH drug misses main goal of midstage tr... - https://goo.gl/4AeNyM - #Drug, #Galectin, #Goal, #Main, #Midstage, #Misses, #NASH, #Nutrition, #Tr
Galectin says NASH drug misses main goal of midstage tr... - https://wp.me/p8XyML-dvz - #Drug, #Galectin, #Goal, #Main, #Midstage, #Misses, #NASH, #Tr
Here's Why These Two Small Cap Biotechs Just Collapsed
Here’s Why These Two Small Cap Biotechs Just Collapsed
In biotech so far this week, we’ve had plenty of fundamental updates to drive volatility across the space. Here are two of the most talked about as we head into the US open on Wednesday. The two companies in focus are CEL-SCI Corporation (NYSEMKT:CVM) and Galectin Therapeutics Inc (NASDAQ:GALT). Let’s kick things off with the former, CEL-SCI. The company announced on Tuesday that the FDA had put…
View On WordPress
OnDemand Webinar Now Available - Galectin-3 Treatment for Heart Failure
Dan Limbach
This webinar just became available as an OnDemand archive of the May 26, 2011 event. Galectin-3: Enabling a New Pharmaceutical Paradigm in Treatment of Heart Failure
This session will provide a unique look at the role of the protein galectin-3 in pharmacological treatment of heart failure. Galectin-3 may transform heart failure from a signs and symptoms based definition of disease to one based on distinct disease processes. Galectin-3 segmentation may be relevant for efficacy of certain drug classes and galectin-3 inhibition may one day offer a new approach to disease modifying therapy in heart failure.
Complementary Webinar. Sponsored by BG Medicine.
View the webinar
Free Webinar: What are Galectins and how can they advance heart failure treatment?
Dan Limbach
Our next webinar will be on May 26 at 12:00pm EST. Galectin-3: Enabling a New Pharmaceutical Paradigm in Treatment of Heart Failure
Register Now
This session will provide a unique look at the role of the protein galectin-3 in pharmacological treatment of heart failure. Galectin-3 may transform heart failure from a signs and symptoms based definition of disease to one based on distinct disease processes. Galectin-3 segmentation may be relevant for efficacy of certain drug classes and galectin-3 inhibition may one day offer a new approach to disease modifying therapy in heart failure.
Sponsored by BG Medicine and brought to you by PharmaVOICE.
Register Now
